KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Sales (2016 - 2025)

Historic Return on Sales for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to 0.4%.

  • Rigel Pharmaceuticals' Return on Sales rose 1800.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 3800.0%. This contributed to the annual value of 0.1% for FY2024, which is 3100.0% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Return on Sales is 0.4%, which was up 1800.0% from 0.59% recorded in Q2 2025.
  • Rigel Pharmaceuticals' Return on Sales' 5-year high stood at 0.59% during Q2 2025, with a 5-year trough of 1.64% in Q1 2022.
  • Moreover, its 5-year median value for Return on Sales was 0.2% (2023), whereas its average is 0.24%.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Return on Sales was 11300bps (2022), while the steepest drop was -21300bps (2022).
  • Over the past 5 years, Rigel Pharmaceuticals' Return on Sales (Quarter) stood at 1.11% in 2021, then surged by 102bps to 0.03% in 2022, then decreased by -25bps to 0.02% in 2023, then skyrocketed by 1108bps to 0.25% in 2024, then surged by 62bps to 0.4% in 2025.
  • Its Return on Sales stands at 0.4% for Q3 2025, versus 0.59% for Q2 2025 and 0.21% for Q1 2025.